Pharmacologic reperfusion therapy for acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 14, Issue 3, 2002, Pages 179-196

  Lowe, Harry C ^a   Mac Neill, Briain D ^a   Van De Werf, Frans ^b   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Myocardial infarction; Reperfusion; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ALTEPLASE; ANISTREPLASE; ANTITHROMBOCYTIC AGENT; CD11 MONOCLONAL ANTIBODY; CD18 MONOCLONAL ANTIBODY; DALTEPARIN; DUTEPLASE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FLUOSOL; HEPARIN; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; MONTEPLASE; NADROPARIN; PADGEM PROTEIN ANTAGONIST; PAMITEPLASE; PLASMINOGEN ACTIVATOR INHIBITOR; POLOXAMER; PROUROKINASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADJUVANT THERAPY; ANTIBODY RESPONSE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEVICE; DOSE RESPONSE; DRUG BINDING; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; FLOW KINETICS; HEART MUSCLE REPERFUSION; HUMAN; HYPOTENSION; INHIBITION KINETICS; INTRACORONARY INFUSION; ISCHEMIA; META ANALYSIS; MORTALITY; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; REVIEW; STENT; TIME; TISSUE PERFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING; VASCULAR PATENCY;

ANIMALS; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION;

EID: 0041914042     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025050208649     Document Type: Review

References (155)

1. Ryan TJ, Anderson JL, Antman EM. ACC/AHA guidelines for the management of patients with acute myocardial infarction. Journal of the American College of Cardiology 1996;28:1238-1428.
2. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, Ed. Heart Disease, a Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders Co. 1997:1184-1288.
3. Topol EJ. Acute myocardial infarction: Thrombolysis. Heart 2000;83:122-126.
4. Kuch B, Bolte HD, Hoermann A, Meisinger C, Loewel H. What is the real hospital mortality from acute myocardial infarction? Epidemiological vs. clinical view. European Heart Journal 2002;23:714-720.
5. ISIS 2 investigators. ISIS-2 (Second International Study of Infarct Survival Collaboration Group). Lancet 1988;ii:349-360.
6. GUSTO investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001;357:1905-1914.
7. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early h of transmural myocardial infarction. New England Journal of Medicine 1980;303:897-902.
8. Davies MJ, Woolf N, Robertson WB. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. British Heart Journal 1976;38:659-664.
9. Tillett WS, Garner RI. The fibrinolytic activity of hemolytic streptococci. Journal of Experimental Medicine 1933;58:485-502.
10. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. Journal of Clinical Investigation 1948;28:173-190.
11. Lew AS, Laramee P, Cercek B, Shah PK, Ganz W. The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation 1985;72:1321-1326.
12. Schroeder R, Biamino G, Von Leitner ER, et al. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation 1983;67:536-548.
13. Elliott JM, Cross DB, Cederholm-Williams SA, White HD. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. American Journal of Cardiology 1993;71:640-645.
14. Estess JM, Moliterno DJ. Thrombolytic therapy for acute myocardial infarction. Catheterization and Cardiovascular Interventions 2001;53:489-498.
15. Topol EJ. Thrombolytic intervention. In: Topol EJ, Ed. Textbook of Interventional Cardiology. Philadelphia: WB Saunders; 1994:68-111.
16. Collen D, Topol EJ, Tiefenbrunn AJ, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized, placebo-controlled trial. Circulation 1984;70:1012-1017.
17. Collen D, Stassen JM, Marafino BJ Jr, et al. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 1984;231:146-152.
18. Sobel BE. The language of lysis: A proposal to standardize the nomenclature. Journal of the American College 1999;34:1226-1227.
19. Topol EJ, Bell WR, Weisfeldt ML. Coronary thrombolysis with recombinant tissue-type plasminogen activator: A hematologic and pharmacologic study. Annals of Internal Medicine 1985;103:837-843.
20. Topol EJ, Ciuffo AA, Pearson TA, et al. Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion. Journal of the American College of Cardiology 1985;5:85-91.
21. Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. American Journal of Medicine 1988;85:353-359.
22. Verstraete M, Bleifield W, Brower RW, et al. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985;2:965-969.
23. Verstraete M, Bory M, Collen D, et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction (ECSG-2). Lancet 1985;1:842-847.
24. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-154.
25. GISSI: Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397-401.
26. Maggioni AP, Franzosi MG, Farina ML, et al. Cerebrovascular events after myocardial infarction: Analysis of the GISSI trial. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). British Medical Journal 1991;302:1428-1431.
27. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. New England Journal of Medicine 1993;329:1615-1622.
28. Simes RJ, Topol EJ, Holmes DR Jr., et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.
29. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977;56:786-794.
30. Ellis SG, Henschke CI, Sandor T, Wynne J, Braunwald E, Kloner RA. Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J Am Coll Cardiol 1983;1:1047-1055.
31. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin blockade with integrilin in acute myocardial. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-854.
32. Antman EM, Guigliano R, Gibson C, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999;99:2720-2732.
33. The strategies for patency enhancement in the emergency department (SPEED) group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000;101:2788-2794.
34. Karagounis L, Sorensen SG, Menlove RL, et al. Does Thrombolysis in Myocardial Infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Journal of the American College of Cardiology 1992;19:1-10.
35. Vogt A, Von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarct related artery after thrombolysis for acute myocardial infarction on short-term mortality: A retrospective analysis of four German multicenter studies. Journal of the American College of Cardiology 1993;21:1391-1395.
36. Lincoff AM, Topol EJ. Illusion of reperfusion: Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;88:1361-1374.
37. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732.
38. GUSTO investigators. An international, multicenter, randomized comparison of reteplase with alteplase for acute myocardial infarction. New England Journal of Medicine 1997;337:1118-1123.
39. Gibson CM, Cannon CP, WL D, et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;93:879-888.
40. Amos DJ, French JK, Andrews J, et al. Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy. American Heart Journal 2001;141:586-591.
41. Barbagelata NA, Granger CB, Oqueli E, et al. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: A pooled analysis. American Heart Journal 1997;133:273-282.
42. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion following successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.
43. Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT. Mediation of occlusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988;77:678-684.
44. Eidt JF, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine arteries with endothelial injury. Journal of Clinical Investigation 1992;84:18-27.
45. Dellborg M, Topol EJ, Swedborg K. Dynamic ST segment vector-cardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. American Heart Journal 1991;68:1564-1569.
46. Kwon K, Freedman B, Wilcox I, et al. The unstable ST segment early after thrombolysis for acute infarction and its usefulness as a marker of recurrent coronary occlusion. American Journal of Cardiology 1991;67:109-115.
47. Maes A, Van De Werf F, Nuyts J, Bormans G, Desmet W, Mortelmans L. Impaired myocardial tissue perfusion early after successful thrombolysis. Circulation 1995;92:2072-2078.
48. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993-1999.
49. Porter TR, Li S, Oster R, et al. The clinical implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of thrombolysis in myocardial infarction (TIMI) 3 flow in patients with acute myocardial infarction. American Journal of Cardiology 1998;82:1173-1177.
50. Sakuma T, Hayashi Y, Sumii K, Imazu M, Yamakido M. Prediction of short and immediate term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization. Journal of the American College of Cardiology 1998;32:890-897.
51. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-772.
52. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
53. De Lemos JA. ST-segment resolution as a marker of epicardial and myocardial reperfusion after thrombolysis: Insights from the TIMI 14 and in TIME-II trials. J Electrocardiol 2000;33(Suppl):67-72.
54. Roe MT, Ohman EM, Maas AC, et al. Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion. Journal of the American College of Cardiology 2001;37:9-18.
55. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: Basic science and clinical correlates. Heart 2002;87:162-168.
56. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-580.
57. Lowe HC, Houser SL, MacNeill BD, Aretz T, Oesterle SN, Palacios IF. Significant atheromatous debris following uncomplicated vein graft direct stenting: Evidence supporting routine use of distal protection devices. Journal of Invasive Cardiology 2002;14:640-641.
58. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2000;300:729-735.
59. Rusnak JM, Kopecky SL, Clements IP, et al. An anti-CD-11/CD 18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). American Journal of Cardiology 2001;88:482-487.
60. Ross A, Gibbons R, Kloner RA, Marder VJ, Stone GW. Acute myocardial infarction study of adenosine (AMISTAD II). Journal of the American College of Cardiology 2002;39:883-886.
61. ASSENT-2 investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double blind randomised trial. Lancet 1999;354:716-722.
62. Rogers WJ, Bowlby IJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): Observations from the national registry of myocardial infarction. Circulation 1994;90:2103-2114.
63. Van De Werf F, Barron HV, Armstrong PW, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: A comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22:2253-2261.
64. Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk of intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Annals of Internal Medicine 1998;129:597-604.
65. Califf RM. Combination therapy for acute myocardial infarction: Fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. American Heart Journal 2000;139:S33-S37.
66. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet ASSENT 3 investigators; 358:605-613.
67. Kostis JB, Liao W, Beierle FA, et al. Single-bolus regimen of lanoteplase (nPA) in acute myocardial infarction: Hemostatic evaluation versus tPA in the InTIME study. Journal of the American College of Cardiology 1999;33:325A.
68. Martin U, Von Moolendorff E, Akpan W, et al. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clinical Pharmacological Therapeutics 1991;50:429-436.
69. Verstraete M. Third-generation thrombolytic drugs. American Journal of Medicine 2000;109:52-58.
70. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
71. International Joint Efficacy Comparison of Thrombolytics. Randomized, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;346:329-336.
72. The GUSTO investigators. A comparison of reteplase with alteplase for acute myocardial infarction. New England Journal of Medicine 1997;337:1118-1123.
73. Van Der Werf F, Cannon CP, Luyten A, et al. Safety assessment of single bolus administration of TNK-tPA in acute myocardial infarction. American Heart Journal 1999;139:786-791.
74. Den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of weight-adjusted single bolus plasminogen activator in patients with myocardial infarction; A double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998;98:2117-2125.
75. The inTIME Investigators. Intravenous nPA for the treatment of infarcting myocardium early. European Heart Journal 2000;21:2005-2013.
76. Laroche Y, Heymans S, Capaert S, De Cock F, Demarsin E, Collen D. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 2000;96:1425-1432.
77. Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Circulation 1995;92:2044-2049.
78. Sinnaeve P, Van De Werf F. Thrombolytic therapy. State of the art. Thrombosis Research 2001;103:S71-S79.
79. Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuming WD. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994;90:421-426.
80. Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995;91:1540-1544.
81. Turpie AGC, Antman EM. Low-molecular weight heparins in the treatment of acute coronary syndromes. Archives in Internal Medicine 2001;161:1484-1490.
82. Granger CB. Acute coronary syndromes: Introducing new therapies into established guidelines. Modern Medicine 2001; spring (suppl).
83. Ryan TJ, Antmann EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial: Executive summary and recommendations. Circulation 1999;100:1016-1030.
84. The ASSENT investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
85. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low molecular weight heparin preparations the same? Semin Thromb Hemost 1996;22:77-91.
86. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-1649.
87. Van De Werf F. ASSENT-3: Implications for future trial design and clinical practice. European Heart Journal 2001;23:911-912.
88. Wallentin L, Dellborg DM, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study. Clin Cardiol 2001;24(3 Suppl.).
89. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial. Lancet 2001;358:1855-1863.
90. The direct thrombin inhibitor trialist's collaborative group. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.
91. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes. Present and future. Circulation 2002;105:1004-1011.
92. Wallis RB. Hirudins: From leeches to man. Seminars in Thromb Hemost 1996;22:185-196.
93. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. Journal of the American College of Cardiology 1998;31:1493-1498.
94. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
95. Antman EM. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624-1630.
96. GUSTO investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 1994;90:1631-1637.
97. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: Results of the HIT-4 trial. Journal of the American College of Cardiology 1999;34:966-973.
98. Vermeer F, Vahanian A, Fels PW, et al. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study. J Thrombosis and Thrombolysis 2000;10:233-240.
99. Van De Werf F. New data in treatment of acute coronary syndromes. American Heart Journal 2001;142:S16-S21.
100. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. European Heart Journal 2001;22:1716-1724.
101. Fernandez-Ortiz A, Jang IK, Fuster V. Antiplatelet and antithrombin therapy. Coron Artery Dis 1994;5:297-305.
102. Patrono C. Aspirin as an antiplatelet drug. New England Journal of Medicine 1994;330:187-194.
103. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-231.
104. Goa KL, Noble S. Eptifibatide. Drugs 1999;57:439-462.
105. McClellan KJ, Goa KL. Tirofiban. Drugs 1998;56:1067-1080.
106. Dooley M, Goa KL. Lamifiban. Drugs 1999;57:215-221.
107. Giugliano RP, McCabe CH, Sequeira RF, et al. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials. Am Heart J 2000;140:81-93.
108. Cannon CP. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol 2000;23(Suppl 6):V114-27.
109. Sabatine MS, Jang IK. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. The American Journal of Medicine 2000;109:224-237.
110. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and aVb3 integrins. Circulation 1998;98:1085-1091.
111. Ambrose JA, Hawkey M, Badimon JJ, et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol 2000;86:150-152.
112. Tcheng JE, Kereikes DJ, Braden GA, et al. Readministration of abciximab: Interim report of the Reopro Readministratin Registry. American Heart Journal 1999;138:S33-S38.
113. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1998;98:2695-2675.
114. Li RH, Herrman HC. Facilitated percutaneous coronary intervention: A novel concept in expediting and improving acute myocardial infarction care. American Heart Journal 2000;140:S125-S135.
115. Gawaz M, Neumann FJ, Dickfield T, et al. Vitronectin receptor mediates platelet adhesion to the luminal aspect of endothelial cells: Implications for reperfusion in acute myocardial infarction. Circulation 1997;96:1809-1818.
116. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 h of acute myocardial infarction treatment. The GUSTO III platelet study. Journal of the American College of Cardiology 1998;31:1466-1473.
117. Lincoff AM. GUSTO IV; Expanding therapeutic options in acute coronary syndromes. American Heart Journal 2000;140:S103-S114.
118. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381-389.
119. PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. Journal of the American College of Cardiology 1998;95:846-854.
120. Ronner E, Van Kesteren HA, Zijnen P, et al. Safety and efficacy of eptifibatide vs. placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; A phase II dose escalation, randomized, double-blind study. European Heart Journal 2000;21:1530-1536.
121. Verheught FW. Risk and benefit of half-dose lytic pls abciximab versus lytic alone for ST-elevation myocardial infarction: A meta-analysis. Journal of the American College of Cardiology 2002;39:828A.
122. Moons AHM, Levi M, Peters RJG. Tissue factor and coronary artery disease. Cardiovascular Research 2002;53:313-325.
123. Ardissino D, Merlini PA, Bauer KA, et al. Thrombogenic potential of human coronary atherosclerotic plaques. Blood 2001;98:2726-2729.
124. Bonderman D, Templ A, Jakowitsch J, et al. Coronary noreflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002;99:2794-2800.
125. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodelling. Circulation Research 2001;89:1-2.
126. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995;92:944-949.
127. Lefkovits J, Malycky JL, Rao JS, et al. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombosis in the canine model. Journal of the American College of Cardiology 1996;28:1858-1865.
128. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999;99:1780-1787.
129. Stassens P, Bergum PW, Gansemans Y, et al. Anticoagulant repertoire of the hookworm ancylcostoma caninum. Proc Natl Acad Sci USA 1996;93:2149-2154.
130. Moons AH, Bijsterveld NR, Buller HR, et al. A blinded multicenter dose escalation phase IIa study of the Factor VII/Tissue factor inhibitor recombinant nematode anticoagulant protein c2 in patients undergoing elective percutaneous coronary intervention. Journal of the American College of Cardiology 2002;39:1053A.
131. Arnljots B, Ezban M, Hedner U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. Journal of Vascular Surgery 1997;25:341-346.
132. Golino P, Ragni M, Cirillo P, et al. Antithrombotic effects of recombinant human, active site blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circulation Research 1998;82:39-46.
133. Jang IK, Gold HK, Leinbach RC, Falloon JT, Collen D, Wilcox JN. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arteriosclerosis and Thrombosis 1992;12:948-954.
134. Kelley RF, Refino CJ, O'Connell MP, et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997;89:3219-3227.
135. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 2000:20:2511-2518.
136. Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 2000;102:3032-3038.
137. Avkiran M, Marber MS. Na(+)/H(+) exchange inhibitors for cardioprotective therapy: Progress, problems and prospects. J Am Coll Cardiol 2002;39:747-753.
138. Clozel M, Qiu C, Qiu CS, Hess P, Clozel. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 2002;39:142-147.
139. TIMI study group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. New England Journal of Medicine 1989;320:618-627.
140. Simoons ML, Betriu A, Col J, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous angioplasty. Lancet 1988;1:197-203.
141. Lane DM. Dramatic increase in the use of coronary stents. American Journal of Cardiology 1999;84:1141.
142. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. New England Journal of Medicine 1999;341:1949-1956.
143. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. New England Journal of Medicine 2002;346:957-966.
144. Montalescot GTB, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. New England Journal of Medicine 2001;344:1895-1903.
145. Neumann F-J, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-921.
146. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000;36:1489-1496.
147. Gibson CM. A union in reperfusion: The concept of facilitated percutaneous coronary intervention. Journal of the American College of Cardiology 2000;36:1497-1499.
148. Ross AM. Combination therapies to enhance reperfusion in acute myocardial infarction. Thrombosis Research 2001;103:S81-S90.
149. Cantor WJ, Ohman EM. 'Facilitated' PCI for acute MI: PCI with lysis and platelet inhibition. Curr Interv Cardiol Rep 2001;3:321-329.
150. Jang IK, Bouma BE, Kang DH, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: Comparison with intravascular ultrasound. Journal of the American College of Cardiology 2002;39:604-609.
151. Jang IK, Tearney G, Bouma B. Visualization of tissue prolapse between coronary stent struts by optical coherence tomography: Comparison with intravascular ultrasound. Circulation 2001;104:2754.
152. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aortocoronary bypass grafts. Circulation 2002;105:1285-1290.
153. Frink RJ, Ostrach LH, Rooney PA, Rose J. Coronary thrombosis, ulcerated atherosclerotic plaques and platelet/fibrin microemboli in patients dying with acute coronary disease: A large autopsy study. Journal of Clinical Investigation 1990;2:199-210.
154. Dixon SR, Bartorelli AL, Marcovitz PA, et al. Initial experience with hyperoxemic reperfusion after primary angioplasty for acute myocardial infarction: Results of a pilot study utilizing intracoronary aqueous oxygen therapy. Journal of the American College of Cardiology 2002;39:387-392.
155. Rosenschein U, Brosh D, Halkin A. Coronary ultrasound thrombolysis: From acute myocardial infarction to saphenous vein grafts and beyond. Curr Interv Cardiol Rep 2001.